About our company


The COVID-19 pandemic dominated 2020, and Greiner Bio-One products played an important role.

Above-average business development in 2020

During the 2020 financial year, Greiner Bio-One employed a global workforce of more than 2,300 at 2 8 locations in 20 countries. The company achieved annual sales revenues of EUR 693 million, which represented growth of 36 percent over the preceding year (FY 2019: EUR 509 million).

With the rapid development of the VACUETTE® virus stabilization tube and an intense focus upon research and laboratory products of relevance to COVID-19, Greiner Bio-One is making a key contribution to the conquest of the pandemic. The careful management of production capacity and close cooperation with our customers constitute the basis for an extremely successful business picture.

“Our contribution to overcoming the pandemic lies in the daily supply of reliable products of COVID-19 relevance.”

Rainer Perneker, CEO Greiner Bio-One International GmbH

The pandemic also affected the development of business

This development pattern was largely influenced by the COVID-19 pandemic and there was also an intense focus upon the maintenance of international delivery capabilities and the best possible management of production capacity and the supply bottlenecks in the sourcing market.

The beginning of the pandemic was marked in many countries by a reduction in hospital services to the treatment of emergency cases, the postponement of routine examinations and the closure of laboratories, universities and research bodies, which resulted in a business downturn. In response, Greiner Bio-One acted quickly with new products for the needs of the pandemic and created additional production capacity for items of relevance to COVID-19 with the aim of securing the supply of research and diagnostic facilities.

During the second half-year in particular, large increases in sales revenues were achieved with COVID-19 related products, above all in the USA and Europe. However, although falling raw material costs bolstered the business result, international transport logistics resulted in high additional costs.


2016 – 2020, figures are given in EUR millions
Year 2016 2017 2018 2019 2020
Turnover 452.0 473.0 473.0 509.0 693.0

Greiner Bio-One Company Movie


To us, health is the highest personal priority. This inspires our daily mission of serving life sciences and healthcare professionals with advanced and sustainable products and solutions. It is the passion and dedication of our people that make the difference. With a straightforward approach our global team continuously strives for excellence and closely collaborates with our customers. That is where our product solutions for preanalytics, research and biotechnology come in. We’re here for you worldwide, right where you need us.

Annual Reports Greiner AG

PDF, 13 MB

Core Business

Greiner Bio-One specializes in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries.

The Preanalytics business division, with headquarters in Kremsmünster (Austria), develops and produces innovative collection systems for human and veterinary blood, urine and saliva samples, with the aim of making day-to-day, routine tasks in hospitals, laboratories and doctors’ practices easier and safer. This division also covers customised software solutions (Greiner eHealth Technologies) which ensure greater efficiency and patient safety in the preanalytical process.

Greiner Bio-One’s BioScience division, with headquarters in Frickenhausen (Germany), is one of the leading providers of specialist products for the cultivation and analysis of cell and tissue cultures. Based on decades of experience in the cryopreservation of samples, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, the division also develops and produces microplates for high-throughput screening, which ensure the quickest and most efficient testing of substances and materials in both industry and research.

As an Original Equipment Manufacturer (OEM), Greiner Bio-One is also a solid partner for industry clients working in pharmaceuticals, biotechnology, diagnostics and medical technology and offers customised design development and production processes.

“Our central objective is to ensure that: We embody our values and our conduct is legally and ethically impeccable! The Management Board will do everything in its power to ensure that the standards established in this code of conduct are permanently implemented and respected in all parts of the Group. ”

Axel Kühner, CEO and Hannes Moser CFO / Greiner Holding AG

The Greiner Group, with almost 150 years of history, has become a real global player in the past few years. With more than 125 sites across the globe, we are close to our customers and can flexibly respond to their needs. However, such a complex organization also presents challenges.

We would like this code of conduct to serve as a basis on which our company’s positive development can continue in the long term. The code is rooted in the Greiner philosophy, which focuses on the global orientation of the Group, its attractiveness as an employer and service provider, and excellent conduct. We have set the rules of conduct derived from these principles in stone in the code of conduct and made them available to all employees, customers, and business partners. It should help us to guarantee the integrity of our conduct in the long term.

Our central objective is to ensure that: We embody our values and our conduct is legally and ethically impeccable!

The Management Board will do everything in its power to ensure that the standards established in this code of conduct are permanently implemented and respected in all parts of the Group. It is our deliberate wish and declared aim to set a good example. We invite all employees to join us on this path.

Code of Condcut of the Greiner Group (EN)

Research and development have always been among the drivers for growth in any economic system. Medical technology and biotechnology in particular have, over the last few decades, experienced steady upwards growth. 

The commercial success of Greiner Bio-One is based upon the consistent advancement of modern technologies and techniques. A significant proportion of the company's turnover is invested in R&D. At the company's facilities in Austria and Germany, teams of product specialists from all manner of different disciplines are working on designing and implementing innovative solutions.

At Greiner Bio-One, specialists in microbiology, chemistry, physics and plastics engineering work on the development of new processes and products. Greiner Bio-One has its own state-of-the-art research centre in Kremsmünster (Upper Austria) for the development of molecular biology analysis methods based on DNA arrays. Clinical studies are prepared and performance assessment testing carried out in the company's own clinical laboratory. 

Extensive networks incorporating selected partner firms, public institutions and organisations mean that Greiner Bio-One is always able to identify relevant issues, the latest developments and emerging trends early and then translate them into product solutions.

As a supplier of high-quality products for medical research and manufacturers of diagnostic agents, we bear responsibility for countless analyses that are carried out worldwide in research organisations, laboratories and hospitals using our products. We regard our customers' confidence for 50 years as testimony to the superlative quality standard we offer and also as an obligation to continue improving the quality of our products even further.

Quality comes first at Greiner Bio-One. Our products are expected to deliver the highest quality. All production sites are ISO 9001 and ISO 13485 certified. We also meet countless national and international quality requirements. By using state-of-the-art production technologies, manufacturing under special environmental conditions and deploying highly skilled staff, we are able to continuously improve the quality of our products and processes.

Greiner Bio-One applies a carefully developed quality assurance system to fully meet all customer requirements. Our optimised processes encompass the entire supply chain, starting from careful selection of suppliers through development and product realisation to the controlled sale of our products. All products are labelled in accordance with the applicable statutory provisions and can be traced back to the components and suppliers used. 

The products and process are regularly audited by national and international authorities and authorisation bodies. Each stage of production is constantly and systematically monitored by our staff, to ensure excellent product quality, determine where improvements can be made and optimise this potential. We strive to optimise all processes to the benefit of our customers. Risk management is a core element of our approach to quality.

The best quality management system is only as good as the people who apply it. Special focus is placed on the training, qualification and continued development of the entire Greiner Bio-One team. We regularly hold quality and product training sessions for our staff, at which they are shown how all Greiner Bio-One products are used, and the resulting quality requirements. Through these measures, we can achieve the highest quality standards for our customers on a day-to-day basis. 

We redirected you to your country page. To go back to the previous page, please click the button.

You are not viewing your country page. To switch to your country, please click the button.